Patents by Inventor Tseng-hui Timothy Chen
Tseng-hui Timothy Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240026011Abstract: The invention relates to Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.Type: ApplicationFiled: August 17, 2021Publication date: January 25, 2024Applicant: Takeda Pharmaceutical Company LimitedInventors: Robert B. DuBridge, Tseng-hui Timothy Chen, Patricia Culp, Chad Michael May, Danielle Dettling, Jeremiah Degenhardt
-
Publication number: 20230340159Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.Type: ApplicationFiled: February 22, 2023Publication date: October 26, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Robert B. DuBridge, Tseng-hui Timothy Chen, Patricia A. Culp, Chad Michael May, Danielle Dettling, Jeremiah Daniel Degenhardt
-
Publication number: 20210324072Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.Type: ApplicationFiled: April 12, 2021Publication date: October 21, 2021Inventors: Mark F. Maurer, Tseng-hui Timothy CHEN, Brigitte DEVAUX, Mohan SRINIVASAN, Susan H. JULIEN, Paul O. SHEPPARD, Daniel F. ARDOUREL, Indrani CHAKRABORTY
-
Patent number: 11008390Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.Type: GrantFiled: December 20, 2018Date of Patent: May 18, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Mark F. Maurer, Tseng-hui Timothy Chen, Brigitte Devaux, Mohan Srinivasan, Susan H. Julien, Paul O. Sheppard, Daniel F. Ardourel, Indrani Chakraborty
-
Publication number: 20190112375Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.Type: ApplicationFiled: December 20, 2018Publication date: April 18, 2019Inventors: Mark F. MAURER, Tseng-hui Timothy CHEN, Brigitte DEVAUX, Mohan SRINIVASAN, Susan H. JULIEN, Paul O. SHEPPARD, Daniel F. ARDOUREL, Indrani CHAKRABORTY
-
Patent number: 10189902Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.Type: GrantFiled: December 22, 2015Date of Patent: January 29, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Mark F. Maurer, Tseng-hui Timothy Chen, Brigitte Devaux, Mohan Srinivasan, Susan H. Julien, Paul O. Sheppard, Daniel F. Ardourel, Indrani Chakraborty
-
Publication number: 20160176963Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.Type: ApplicationFiled: December 22, 2015Publication date: June 23, 2016Inventors: Mark F. Maurer, Tseng-hui Timothy Chen, Brigitte Devaux, Mohan Srinivasan, Susan H. Julien, Paul O. Sheppard, Daniel F. Ardourel, Indrani Chakraborty
-
Patent number: 8758757Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.Type: GrantFiled: December 20, 2010Date of Patent: June 24, 2014Assignee: Medarex, L.L.C.Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
-
Publication number: 20110086422Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.Type: ApplicationFiled: December 20, 2010Publication date: April 14, 2011Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
-
Patent number: 7888484Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.Type: GrantFiled: September 29, 2009Date of Patent: February 15, 2011Assignee: Medarex, Inc.Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
-
Publication number: 20100104569Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.Type: ApplicationFiled: September 29, 2009Publication date: April 29, 2010Applicant: MEDAREX, INC.Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
-
Patent number: 7619070Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.Type: GrantFiled: April 23, 2004Date of Patent: November 17, 2009Assignee: Medarex, Inc.Inventors: Josephine M. Cardarelli, Tseng-Hui Timothy Chen, David J. King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
-
Patent number: 6875590Abstract: Novel synthetic leader peptides have been identified. The leader peptides have use in a method of enhancing the secretion of a recombinant polypeptide produced in a host cell. Polynucleotides encoding the novel leader peptides and a method of designing the polynucleotides are described.Type: GrantFiled: June 5, 2001Date of Patent: April 5, 2005Assignee: Corixa CorporationInventors: Tseng-hui Timothy Chen, Brian Schmidt
-
Publication number: 20020072093Abstract: Novel synthetic leader peptides have been identified. The leader peptides have use in a method of enhancing the secretion of a recombinant polypeptide produced in a host cell. Polynucleotides encoding the novel leader peptides and a method of designing the polynucleotides are described.Type: ApplicationFiled: June 5, 2001Publication date: June 13, 2002Inventors: Tseng-hui Timothy Chen, Brian Schmidt